Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

Refractoriness to ruxolitinib in patients with myelofibrosis (MF) was associated with clonal evolution; however, whether genetic instability is promoted by ruxolitinib remains unsettled. We evaluated the mutation landscape in 71 MF patients receiving ruxolitinib (n = 46) and hydroxyurea (n = 25) and...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Cancer J
Päätekijät: Pacilli, Annalisa, Rotunno, Giada, Mannarelli, Carmela, Fanelli, Tiziana, Pancrazzi, Alessandro, Contini, Elisa, Mannelli, Francesco, Gesullo, Francesca, Bartalucci, Niccolò, Fattori, Giuditta Corbizi, Paoli, Chiara, Vannucchi, Alessandro M., Guglielmelli, Paola
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6250726/
https://ncbi.nlm.nih.gov/pubmed/30467377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0152-x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia